| 1 | Circular RNA regulatory role in pathological cardiac remodelling | 6.3 | 22 | Citations (PDF) |
| 2 | miR‐210 as a therapeutic target in diabetes‐associated endothelial dysfunction | 6.3 | 5 | Citations (PDF) |
| 3 | Blood CD45+/CD3+ lymphocyte‐released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019 | 3.1 | 1 | Citations (PDF) |
| 4 | miR-210 overexpression increases pressure overload-induced cardiac fibrosis | 4.6 | 1 | Citations (PDF) |
| 5 | Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1 | 5.5 | 5 | Citations (PDF) |
| 6 | Circulating Non-Coding RNAs as Indicators of Fibrosis and Heart Failure Severity | 4.7 | 9 | Citations (PDF) |
| 7 | Circular PVT1 promotes cardiac fibroblast activation interacting with miR-30a-5p and miR-125b-5p | 8.5 | 8 | Citations (PDF) |
| 8 | Comparing venous wall effects using the empty vein ablation technique with VELEX catheter, endovenous laser ablation and foam sclerotherapy in an animal model | 1.7 | 0 | Citations (PDF) |
| 9 | From cancer to heart fibrosis ‐ GLIPR1 highlights a subset of myofibroblasts responsive to mesenchymal stem cell therapy after myocardial infarction | 6.7 | 2 | Citations (PDF) |
| 10 | LEF1-AS1 Deregulation in the Peripheral Blood of Patients with Persistent Post-COVID Symptoms | 4.4 | 0 | Citations (PDF) |
| 11 | Circular RNA role in Atherosclerosis Development and Progression | 4.7 | 6 | Citations (PDF) |
| 12 | miR-210 locus deletion disrupts cellular homeostasis: an integrated genetic study | 3.4 | 1 | Citations (PDF) |
| 13 | Modulation of hypoxia-sensitive non-coding RNAs following continuous positive airway pressure therapy in obstructive sleep apnea in peripheral blood | 2.7 | 3 | Citations (PDF) |
| 14 | Current status and challenges of multi-omics research using animal models of atherosclerosis | 1.5 | 1 | Citations (PDF) |
| 15 | circARHGAP10 as a candidate biomarker and therapeutic target in myotonic dystrophy type 1 | 5.5 | 1 | Citations (PDF) |
| 16 | Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological/neurodegenerative diseases | 5.5 | 12 | Citations (PDF) |
| 17 | Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease | 35.7 | 49 | Citations (PDF) |
| 18 | Addressing the unsolved challenges in microRNA-based biomarker development: Suitable endogenous reference microRNAs for SARS-CoV-2 infection severity | 8.1 | 11 | Citations (PDF) |
| 19 | Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality | 13.7 | 16 | Citations (PDF) |
| 20 | Coding and Non-Coding Transcriptomic Landscape of Aortic Complications in Marfan Syndrome | 4.4 | 8 | Citations (PDF) |
| 21 | Prediction of COVID‐19 severity using machine learning | 5.5 | 3 | Citations (PDF) |
| 22 | miR-210 is essential to retinal homeostasis in fruit flies and mice | 4.3 | 1 | Citations (PDF) |
| 23 | The COVID-19 legacy: consequences for the human DNA methylome and therapeutic perspectives | 4.6 | 1 | Citations (PDF) |
| 24 | Integration of epigenetic regulatory mechanisms in heart failure | 7.0 | 23 | Citations (PDF) |
| 25 | Cardiovascular complications of diabetes: role of non-coding RNAs in the crosstalk between immune and cardiovascular systems | 9.4 | 21 | Citations (PDF) |
| 26 | Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges | 1.5 | 7 | Citations (PDF) |
| 27 | HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of COVID-19 patients | 6.4 | 10 | Citations (PDF) |
| 28 | circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients | 4.7 | 24 | Citations (PDF) |
| 29 | Dissecting the transcriptome in cardiovascular disease | 5.5 | 35 | Citations (PDF) |
| 30 | miR-210 hypoxamiR in Angiogenesis and Diabetes | 6.3 | 32 | Citations (PDF) |
| 31 | Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129 | 5.5 | 35 | Citations (PDF) |
| 32 | Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene | 5.5 | 21 | Citations (PDF) |
| 33 | Regulatory miRNAs in Cardiovascular and Alzheimer’s Disease: A Focus on Copper | 4.4 | 12 | Citations (PDF) |
| 34 | Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing | 4.4 | 32 | Citations (PDF) |
| 35 | Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation | 13.2 | 84 | Citations (PDF) |
| 36 | Beta-Secretase-1 Antisense RNA Is Associated with Vascular Ageing and Atherosclerotic Cardiovascular Disease | 4.1 | 16 | Citations (PDF) |
| 37 | CircANKRD12 Is Induced in Endothelial Cell Response to Oxidative Stress | 4.7 | 9 | Citations (PDF) |
| 38 | Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality | 3.4 | 14 | Citations (PDF) |
| 39 | Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129 | 5.5 | 22 | Citations (PDF) |
| 40 | Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia | 8.5 | 30 | Citations (PDF) |
| 41 | Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation | 10.9 | 56 | Citations (PDF) |
| 42 | Leveraging non-coding RNAs to fight cardiovascular disease: the EU-CardioRNA network | 2.2 | 17 | Citations (PDF) |
| 43 | Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors | 4.4 | 92 | Citations (PDF) |
| 44 | Mitochondrial–cell cycle cross-talk drives endoreplication in heart disease | 12.5 | 21 | Citations (PDF) |
| 45 | Hypoxia-Induced miR-210 Is Necessary for Vascular Regeneration upon Acute Limb Ischemia | 4.4 | 23 | Citations (PDF) |
| 46 | The epigenetic implication in coronavirus infection and therapy | 3.9 | 89 | Citations (PDF) |
| 47 | Approaching Sex Differences in Cardiovascular Non-Coding RNA Research | 4.4 | 24 | Citations (PDF) |
| 48 | Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era | 6.4 | 21 | Citations (PDF) |
| 49 | Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases | 4.4 | 10 | Citations (PDF) |
| 50 | Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome | 2.5 | 69 | Citations (PDF) |
| 51 | Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis | 4.7 | 46 | Citations (PDF) |
| 52 | Regulatory RNAs in Heart Failure | 18.1 | 170 | Citations (PDF) |
| 53 | Epigenetic Signaling and RNA Regulation in Cardiovascular Diseases | 4.4 | 26 | Citations (PDF) |
| 54 | Call to action for the cardiovascular side of COVID-19 | 2.2 | 12 | Citations (PDF) |
| 55 | Dysregulation of microRNA expression in diabetic skin | 2.3 | 9 | Citations (PDF) |
| 56 | Long Noncoding Competing Endogenous RNA Networks in Age-Associated Cardiovascular Diseases | 4.4 | 49 | Citations (PDF) |
| 57 | The Dark That Matters: Long Non-coding RNAs as Master Regulators of Cellular Metabolism in Non-communicable Diseases | 2.8 | 59 | Citations (PDF) |
| 58 | Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1 | 4.4 | 50 | Citations (PDF) |
| 59 | P300/CBP‐associated factor regulates transcription and function of isocitrate dehydrogenase 2 during muscle differentiation | 0.6 | 14 | Citations (PDF) |
| 60 | Noncoding RNAs in the Vascular System Response to Oxidative Stress | 6.3 | 29 | Citations (PDF) |
| 61 | Zeb1-Hdac2-eNOS circuitry identifies early cardiovascular precursors in naive mouse embryonic stem cells | 13.7 | 20 | Citations (PDF) |
| 62 | Long Noncoding RNAs and Cardiac Disease | 6.3 | 70 | Citations (PDF) |
| 63 | Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells From Type2 Diabetes Patients | 13.2 | 48 | Citations (PDF) |
| 64 | Circular RNAs in Muscle Function and Disease | 4.4 | 91 | Citations (PDF) |
| 65 | Circular <scp>RNA</scp>s: Methodological challenges and perspectives in cardiovascular diseases | 4.0 | 63 | Citations (PDF) |
| 66 | High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2 | 8.5 | 21 | Citations (PDF) |
| 67 | miR-210 Enhances the Therapeutic Potential of Bone-Marrow-Derived Circulating Proangiogenic Cells in the Setting of Limb Ischemia | 10.2 | 45 | Citations (PDF) |
| 68 | Increased BACE1-AS long noncoding RNA and β-amyloid levels in heart failure | 5.5 | 90 | Citations (PDF) |
| 69 | Oxidative Stress-Induced miR-200c Disrupts the Regulatory Loop Among SIRT1, FOXO1, and eNOS | 6.3 | 127 | Citations (PDF) |
| 70 | Age-dependent increase of oxidative stress regulates microRNA-29 family preserving cardiac health | 3.4 | 65 | Citations (PDF) |
| 71 | CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients | 5.5 | 66 | Citations (PDF) |
| 72 | The double life of cardiac mesenchymal cells: Epimetabolic sensors and therapeutic assets for heart regeneration 2017, 171, 43-55 | | 12 | Citations (PDF) |
| 73 | Overexpression of miR-210 and its significance in ischemic tissue damage | 3.4 | 49 | Citations (PDF) |
| 74 | Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1 | 3.4 | 58 | Citations (PDF) |
| 75 | Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing | 3.4 | 135 | Citations (PDF) |
| 76 | microRNAs in ischaemic cardiovascular diseases | 0.1 | 9 | Citations (PDF) |
| 77 | Long noncoding RNA dysregulation in ischemic heart failure | 6.4 | 190 | Citations (PDF) |
| 78 | MicroRNA-222 regulates muscle alternative splicing through Rbm24 during differentiation of skeletal muscle cells | 8.5 | 49 | Citations (PDF) |
| 79 | Noncoding RNA in age-related cardiovascular diseases | 3.8 | 104 | Citations (PDF) |
| 80 | Sirtuin function in aging heart and vessels | 3.8 | 93 | Citations (PDF) |
| 81 | Proliferation of Multiple Cell Types in the Skeletal Muscle Tissue Elicited by Acute p21 Suppression | 10.2 | 8 | Citations (PDF) |
| 82 | Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210 | 3.8 | 138 | Citations (PDF) |
| 83 | p75NTR-dependent activation of NF-κB regulates microRNA-503 transcription and pericyte–endothelial crosstalk in diabetes after limb ischaemia | 13.7 | 130 | Citations (PDF) |
| 84 | Magnetic Resonance Imaging Allows the Evaluation of Tissue Damage and Regeneration in a Mouse Model of Critical Limb Ischemia | 2.3 | 31 | Citations (PDF) |
| 85 | Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2 | 2.3 | 28 | Citations (PDF) |
| 86 | Nitric Oxide, Oxidative Stress, andp66ShcInterplay in Diabetic Endothelial Dysfunction | 6.3 | 106 | Citations (PDF) |
| 87 | Noncoding RNAs: Emerging Players in Muscular Dystrophies | 6.3 | 18 | Citations (PDF) |
| 88 | Hypoxia-Induced miR-210 Modulates Tissue Response to Acute Peripheral Ischemia | 6.3 | 51 | Citations (PDF) |
| 89 | HypoxamiR Regulation and Function in Ischemic Cardiovascular Diseases | 6.3 | 88 | Citations (PDF) |
| 90 | Epigenetic mechanisms of hyperglycemic memory | 2.6 | 44 | Citations (PDF) |
| 91 | Plasma microRNAs as biomarkers for myotonic dystrophy type 1 | 0.7 | 64 | Citations (PDF) |
| 92 | The Histone Acetylase Activator Pentadecylidenemalonate 1b Rescues Proliferation and Differentiation in the Human Cardiac Mesenchymal Cells of Type 2 Diabetic Patients | 4.2 | 74 | Citations (PDF) |
| 93 | Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases | 4.4 | 204 | Citations (PDF) |
| 94 | Transcriptional Profiling of Hmgb1-Induced Myocardial Repair Identifies a Key Role for Notch Signaling | 10.2 | 28 | Citations (PDF) |
| 95 | Oxidative Stress and MicroRNAs in Vascular Diseases | 4.4 | 183 | Citations (PDF) |
| 96 | A Nitric Oxide-dependent Cross-talk between Class I and III Histone Deacetylases Accelerates Skin Repair | 2.2 | 82 | Citations (PDF) |
| 97 | Enhancement of lysine acetylation accelerates wound repair | 0.9 | 44 | Citations (PDF) |
| 98 | Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs | 3.8 | 126 | Citations (PDF) |
| 99 | Hypoxia-inducible Factor 1-α Induces miR-210 in Normoxic Differentiating Myoblasts | 2.2 | 94 | Citations (PDF) |
| 100 | MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients | 4.2 | 225 | Citations (PDF) |
| 101 | ROD1 Is a Seedless Target Gene of Hypoxia-Induced miR-210 | 2.3 | 36 | Citations (PDF) |
| 102 | Deregulated MicroRNAs in Myotonic Dystrophy Type 2 | 2.3 | 85 | Citations (PDF) |
| 103 | Deregulation of microRNA-503 Contributes to Diabetes Mellitus–Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia | 18.1 | 391 | Citations (PDF) |
| 104 | Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1 | 0.7 | 119 | Citations (PDF) |
| 105 | MicroRNA‐155 targets theSKIgene in human melanoma cell lines | 2.9 | 80 | Citations (PDF) |
| 106 | miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition | 13.3 | 437 | Citations (PDF) |
| 107 | microRNAs as peripheral blood biomarkers of cardiovascular disease | 2.5 | 67 | Citations (PDF) |
| 108 | miR‐210: More than a silent player in hypoxia | 2.9 | 274 | Citations (PDF) |
| 109 | Knockdown of Cyclin-dependent Kinase Inhibitors Induces Cardiomyocyte Re-entry in the Cell Cycle | 2.2 | 89 | Citations (PDF) |
| 110 | microRNA: Emerging therapeutic targets in acute ischemic diseases 2010, 125, 92-104 | | 172 | Citations (PDF) |
| 111 | Transcription Factor NF-Y Induces Apoptosis in Cells Expressing Wild-Type p53 through E2F1 Upregulation and p53 Activation | 3.8 | 36 | Citations (PDF) |
| 112 | MicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease | 18.1 | 440 | Citations (PDF) |
| 113 | Regulation of the endothelial cell cycle by the ubiquitin-proteasome system | 5.5 | 47 | Citations (PDF) |
| 114 | Circulating microRNAs are new and sensitive biomarkers of myocardial infarction | 2.2 | 760 | Citations (PDF) |
| 115 | MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients | 2.5 | 135 | Citations (PDF) |
| 116 | p66ShcA modulates oxidative stress and survival of endothelial progenitor cells in response to high glucose | 5.5 | 64 | Citations (PDF) |
| 117 | An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210 | 2.2 | 260 | Citations (PDF) |
| 118 | Common micro‐RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia | 0.6 | 246 | Citations (PDF) |
| 119 | Platelet-Derived Growth Factor-Receptor α Strongly Inhibits Melanoma Growth In Vitro and In Vivo | 7.0 | 35 | Citations (PDF) |
| 120 | Microrna-221 and Microrna-222 Modulate Differentiation and Maturation of Skeletal Muscle Cells | 2.3 | 211 | Citations (PDF) |
| 121 | Hypoxia response and microRNAs: no longer two separate worlds | 4.0 | 190 | Citations (PDF) |
| 122 | HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment | 7.5 | 260 | Citations (PDF) |
| 123 | Protein Phosphatase 2A Subunit PR70 Interacts with pRb and Mediates Its Dephosphorylation | 2.5 | 56 | Citations (PDF) |
| 124 | MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3 | 2.2 | 850 | Citations (PDF) |
| 125 | Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling | 13.2 | 117 | Citations (PDF) |
| 126 | p66ShcA and Oxidative Stress Modulate Myogenic Differentiation and Skeletal Muscle Regeneration after Hind Limb Ischemia | 2.2 | 73 | Citations (PDF) |
| 127 | Molecular mechanisms of cardiomyocyte regeneration and therapeutic outlook | 7.4 | 17 | Citations (PDF) |
| 128 | Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: Evidence for specialized functions of paxillin | 5.5 | 9 | Citations (PDF) |
| 129 | Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF | 7.5 | 112 | Citations (PDF) |
| 130 | Impaired T- and B-cell development in Tcl1-deficient miceBlood, 2005, 105, 1288-1294 | 4.2 | 34 | Citations (PDF) |
| 131 | p66
ShcA
Modulates Tissue Response to Hindlimb Ischemia | 18.1 | 113 | Citations (PDF) |
| 132 | Hypoxia Inhibits Myogenic Differentiation through Accelerated MyoD Degradation | 2.2 | 138 | Citations (PDF) |
| 133 | Enhanced Arteriogenesis and Wound Repair in Dystrophin-Deficient
mdx
Mice | 18.1 | 53 | Citations (PDF) |
| 134 | p21Waf1/Cip1/Sdi1 mediates shear stress-dependent antiapoptotic function | 5.5 | 24 | Citations (PDF) |
| 135 | Active Localization of the Retinoblastoma Protein in Chromatin and Its Response to S Phase DNA Damage | 13.3 | 112 | Citations (PDF) |
| 136 | MyoD Stimulates
RB
Promoter Activity via the CREB/p300 Nuclear Transduction Pathway | 2.5 | 76 | Citations (PDF) |
| 137 | Oxidative Stress Induces Protein Phosphatase 2A-dependent Dephosphorylation of the Pocket Proteins pRb, p107, and p130 | 2.2 | 115 | Citations (PDF) |
| 138 | p19ARF targets certain E2F species for degradation | 7.5 | 170 | Citations (PDF) |
| 139 | Regulation of endogenous E2F1 stability by the retinoblastoma family proteins | 7.5 | 36 | Citations (PDF) |
| 140 | The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. | 4.6 | 215 | Citations (PDF) |
| 141 | Blockade of YAP Mechanoactivation Prevents Neointima Formation and Adverse Remodeling in Arterialized Vein Grafts | 4.0 | 2 | Citations (PDF) |
| 142 | miR-210 promotes the anti-inflammatory phenotype and M2 polarization in murine macrophages | 4.9 | 2 | Citations (PDF) |
| 143 | Non-coding RNAs as novel biomarkers and therapeutic targets in breast cancer | 4.0 | 2 | Citations (PDF) |
